CandlesenseCandlesense
News/Companies/SCNI

SCNI News

Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances

SCNI

JERUSALEM, Dec. 2, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company developing innovative inflammation and immunology (I&I) therapeutics and operating a growing boutique CDMO business unit, today reported its...

December 2, 2025
Read more →

Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet

SCNI

(NASDAQ:SCNI) JERUSALEM, Sept. 2, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing novel and innovative biological drug candidates for the treatment of inflammation and immunology (I&I) related diseases...

September 2, 2025Earnings
Read more →

Scinai Immunotherapeutics Receives Italian Government Clearance To Potentially Acquire Pincell S.r.l.

SCNI

June 5, 2025
Read more →

Scinai Immunotherapeutics Reports Q1 Revenues Of $586,000; Exits Quarter With Cash & Equivalents Worth $1.01M

SCNI

May 30, 2025
Read more →

Scinai to Discuss Monoclonal Antibody PC111 for Rare Skin Diseases in Upcoming Webinar

SCNI

May 1, 2025
Read more →

Scinai Immunotherapeutics Signs An Option Agreement To Acquire Rare Disease Company Pincell And Its Novel Antibody For Treating Severe Dermatological Conditions; No Financial Terms Of Transaction Disclosed; Files An Application For €12 Million Grant To Fu

SCNI

March 27, 2025
Read more →

Scinai Signs $10M Standby Equity Agreement, Retains Control Over Stock Sales to Yorkville

SCNI

March 5, 2025
Read more →

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

SCNI

May 21, 2024
Read more →

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

SCNI

May 20, 2024
Read more →